DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

被引：37

作者：

Chapple, C. ^{[1
]}

Wyndaele, J. J. ^{[2
]}

Van Kerrebroeck, P. ^{[3
]}

Radziszewski, P. ^{[4
]}

Dvorak, V. ^{[5
]}

Boerrigter, P. ^{[6
]}

机构：

[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

[2] Univ Antwerp, Fac Med, B-2020 Antwerp, Belgium

[3] Univ Med Ctr Maastricht, Maastricht, Netherlands

[4] Med Univ Warsaw, Dept Urol, Warsaw, Poland

[5] Private Obstet Gynecol Clin, Brno, Czech Republic

[6] Astellas Pharma, Med & Clin Dev, Global Dev EU, Leiderdorp, Netherlands

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期

关键词：

D O I：

10.1016/S1569-9056(10)60758-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：249 / 249

页数：1

共 50 条

[41] EFFECTS OF THE β3-ADRENOCEPTOR AGONIST, MIRABEGRON, ON QUALITY OF LIFE IN OLDER PATIENTS WITH OVERACTIVE BLADDER: A POST-HOC ANALYSIS OF POOLED DATA FROM 3 RANDOMISED PHASE 3 TRIALS
Wagg, Adrian
Nitti, Victor
Kelleher, Con
Auerbach, Stephen
Blauwet, Mary Beth
Siddiqui, Emad
JOURNAL OF UROLOGY, 2014, 191 (04): : E339 - E339
[42] Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: A multicenter, double-blind, placebo-controlled, dose-ranging study
Hart, W
Holwerda, NJ
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (05) : 637 - 643
[43] Barnidipine, a Novel Calcium Antagonist for Once-Daily Treatment of Hypertension: A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Wimpeter Hart
Nicolas J. Holwerda
Cardiovascular Drugs and Therapy, 1997, 11 : 637 - 643
[44] Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
Abrams, Paul
Kelleher, Con
Staskin, David
Rechberger, Tomasz
Kay, Richard
Martina, Reynaldo
Newgreen, Donald
Paireddy, Asha
van Maanen, Rob
Ridder, Arwin
EUROPEAN UROLOGY, 2015, 67 (03) : 577 - 588
[45] Evaluation of pharmacokinetics (PK) and safety of fesoterodine 4-and 8-mg once-daily in an 8-week study in pediatric patients with overactive bladder (OAB)
Malhotra, B.
El-Tahtawy, A.
Wang, E.
Darekar, A.
Scholfield, D.
Crook, T.
Reddy, P. P.
EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E510 - U107
[46] CLINICAL EFFICACY AND SAFETY OF A BETA3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND AN ANTIMUSCARINIC AGENT (IMIDAFENACIN) IN FEMALE PATIENTS WITH OVERACTIVE BLADDER: A RANDOMIZED CROSSOVER STUDY
Torimoto, K.
Matsushita, C.
Yamada, A.
Goto, D.
Matsumoto, Y.
Hosokawa, Y.
Hirayama, A.
Fujimoto, K.
NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S396 - S397
[47] Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-Blind, Dose-Ranging, Phase 2 Study (Symphony)
Wein, Alan J.
JOURNAL OF UROLOGY, 2015, 193 (01): : 218 - 219
[48] Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
Cruz, Francisco
EUROPEAN UROLOGY, 2015, 67 (06) : 1189 - 1190
[49] Once-Daily Vibegron 75 mg for Overactive Bladder (OAB) Is Generally Safe and Well Tolerated, and Is Efficacious in Patients Aged ≥65 or ≥75 Years: EMPOWUR Randomized, International, Phase 3 Study
Frankel, J.
Staskin, D.
Varano, S.
Shortino, D.
Jankowich, R.
Mudd, P.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 68 : S217 - S218
[50] The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity
Svalo, Julie
Nordling, Jorgen
Bouchelouche, Kirsten
Andersson, Karl-Erik
Korstanje, Cees
Bouchelouche, Pierre
EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 699 (1-3) : 101 - 105

← 1 2 3 4 5 →